“Francis Medical has a powerfully simple and differentiated technology, supported by an outstanding team. I’m excited to add my knowledge and experience to the group and make a meaningful impact as we strive to bring this transformational technology to urologists and their patients.”
“The Liver-Chip detected nearly 7 out of every 8 drugs that proved hepatoxic in clinical use despite having been deemed to have an appropriate therapeutic window by animal models.”
Digital transformation requires a clear vision, buy-in at every level, and significant investment. Here are three steps to streamline the process.
“We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”
More than 300 scientists will consider the evidence on over 25 virus families and bacteria—as well as “Disease X” (an unknown pathogen that could cause a serious international epidemic)—and recommend a list of priority pathogens that need further research and investment.
Companies must have the right data infrastructure in place to help them determine what their customers want, when they want it and how they want to receive it. One of the most critical elements of this success is connected intelligence, which provides a full view of customer needs and expectations to everyone in the organization.
The $16.6 billion acquisition will bring Abiomed’s breakthough Impella heart pumps into the Johnson & Johnson MedTech portfolio.
The goal of the TAP Pilot is to reduce the time from concept to commercialization of medical devices by facilitating robust engagement early in the process with the FDA, industry and key stakeholders.
Leslie Storms, U.S. president of Ethicon, Martha Shadan, chairwoman of Brilliant Springs Therapeutics, and Kristine Ilaria, vice president of Corporate Development at Smith+Nephew, share lessons learned from their panel “Making Acquisition Strategy Succeed: Perspectives from Both Sides of The Deal.”
The order outlines a “whole-of-government approach” to advance biotechnology and biomanufacturing towards innovative solutions in health, climate change, energy, food security, agriculture, supply chain resilience and national and economic security.